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following hip resurfacing arthroplasty is related to individual
changes over time. Multilevel analysis is a useful approach to
study repeated measures data with missing values.
ARTHRITIS—Patient Reported Outcomes
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OBJECTIVES: To investigate the presence and impact of
response shift (RS) in HRQoL among patients undergoing total
knee replacement (TKR) and explore factors associated with RS.
METHODS: HRQoL of TKR patients was assessed by SF-6D at
0-month (just before surgery: pre-test1), 6 months (pre-test2) and
18 months after surgery (post-test). At 18-month, HRQoL at
0-month and 6-month was evaluated again by “then-test”
approach. RS was calculated as the score difference between
corresponding pre- and then-test. Descriptive analysis was used
for demographics, medical information and satisfaction with
knee surgery (on a 0–10 Likert scale). Wilcoxon Signed Rank
tests were used for comparisons of RS at 0-month and 6-month.
Relationships between RS and external variables were investi-
gated by Mann-Whitney, Kruskal-Wallis tests or Spearman’s cor-
relation. Multiple liner regression (MLR) models were used to
explore factors potentially impacting RS. Unless speciﬁed,
median (interquartile range) was reported and signiﬁcance level
was set at 0.01. RESULTS: Data were analyzed from 74 subjects
[mean (SD) age 68.9 (7.9) years, 81% female, 92% with less than
12 years of education, 72% with acute and 68% with chronic
illness, 10% with past knee surgery history, mean (SD) surgery
satisfaction of 8.0 (1.3)]. SF-6D scores for then-tests at 0-month
[0.48 (0.42, 0.49)] and 6-month [0.72 (0.66, 0.79)] were signiﬁ-
cantly different from respective pre-test scores [0.61 (0.58, 0.68)
at 0-month, 0.69 (0.63, 0.72) at 6-month], both indicating pres-
ence of RS. RS at 0-month was signiﬁcantly larger than that at
6-month. RS at 0-month was not affected by demographic or
medical variables. RS at 6-month was greater in subjects with
higher education (p < 0.01, 16% of variance in MLR). CON-
CLUSION: RS was present and impacted HRQoL assessment
among patients undergoing TKR both just prior to and 6 months
after surgery. RS investigation is thus suggested to be performed
during HRQoL evaluations.
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OBJECTIVES: The aim of this study was to validate Oswestry
hip score which was developed as a patient-completed self-
assessment to provide both Harris and Merle d’Aubigne hip
score with added content to estimate hip range of motion.
METHODS: A total of 161 patients completed the Oswestry hip
score, WOMAC Index, Harris hip score (HHS) and the Oxford
hip score (OHS at two different occasions. Validity was tested by
comparing the domains of the Oswestry hip score to WOMAC,
HHS and OHS. RESULTS: The reliability of this new score was
established by the test-retest method. Cronbach’s alpha was 0.7,
which is considered a good measure of internal consistency.
Content validity of the Oswestry hip score was established by the
validated domains of pain, function and range of motion of HHS
and Merle score. Analysis of frequency of response distribution
showed normal ﬂoor and ceiling effect for any of the domains of
the Oswestry hip score. Multimethod multitrait matrix analysis
was used to establish the construct validity of the Oswestry hip
score. There was good correlation between pain and function
domains (p < 0.001). Moderate correlation was found among
clinical assessment of hip movement and movement domains of
Oswestry hip score (Pearson’s r = 0.55; p0.001). CONCLU-
SION: A positive construct validity and high correlation with
WOMAC, Oxford Hip Score and Harris hip score shows that the
Oswestry hip score can give an adequate measure of hip joint
function. It can be completed by patients themselves and is
therefore ideal for long-term and large scale collection of clinical
outcome data.
DIABETES—Clinical Outcomes Studies
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OBJECTIVES: To assess the level of adequate glycemic control
in real life practice settings in Hungary in adult patients with type
2 diabetes mellitus (T2DM) who added a sulfonylurea (SU)
or glitazone (PPAR) to ongoing metformin(MF) monotherapy.
METHODS: Retrospective clinical chart reviews and patient
surveys at the point of visit (January 2006–March 2007) were
conducted in Hungary. Patients were °Ý30 years of age at time of
T2DM diagnosis and added a SU or PPAR to previous MF
monotherapy irrespective of whether those drugs were discon-
tinued afterwards. Information on A1C, medication use and
co-morbid conditions was extracted from clinical charts, for up
to a 7 month baseline period (MF monotherapy) and for a
minimum of one year follow-up period (between therapy
addition and date of survey). Glycemic goal attainment at
A1C < 6.5% was assessed according to the IDF (2005) recom-
mendations using the last available A1c value during follow-up.
RESULTS: In total, 401 patients (85% SU + MF and 15%
PPAR + MF) of which 52.1% males, were recruited. For the
SU + MF and PPAR + MF groups respectively: mean age was
61.0(SD = 9.3) and 57.9(SD = 11.4) years; duration of diabetes
was 7.53(SD = 5.1) and 6.6(SD = 4.2) years; A1C during MF
monotherapy was 8.4(SD = 1.6) and 7.6(SD = 1.4); A1C since
combination therapy was 7.9(SD = 1.3) and 7.1(SD = 1.3).
Patients at goal after addition of SU was 21.7% and 26.7% were
at goal after addition of PPAR. In total, 14.2% initiated insulin
since the addition of SU to MF, 3.3% initiated insulin since the
addition of PPAR to MF. CONCLUSION: Several differences
were seen between the groups who added SU or PPAR to MF,
including age, duration of diabetes and A1C values. In both
groups, approximately three quarters of patients with T2DM
failed to attain glycemic control goal since initiating oral combi-
nation therapy.
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